Quercetin activates lysosomal function to ameliorate neuroinflammation and cognitive deficits in chronic cerebral hypoperfusion

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Chronic cerebral hypoperfusion (CCH) is a major contributor to vascular cognitive impairment (VCI), often resulting in progressive learning and memory deficits. Quercetin (Qu), a natural flavonoid with potent anti-inflammatory and antioxidant properties, demonstrates neuroprotective potential against ischemic injury, yet its mechanism of action remains incompletely understood. In this study, a rat model of CCH was established by bilateral common carotid artery occlusion, followed by Qu administration at doses of 20, 40, and 80 mg·kg⁻¹. In parallel, HT22 cells subjected to oxygen-glucose deprivation (OGD) were treated with Qu at 5, 10, or 20 μmol·L⁻¹. Behavioral tests, histological staining, ELISA, and Western blot were used to assess cognitive performance, neuronal injury, lysosomal activity, NF-κB pathway activation, and inflammatory cytokine levels. Hippocampal RNA sequencing was also performed. Our results demonstrate that Qu greatly improved cognitive performance and attenuated neuronal damage in both the cerebral cortex and hippocampus. Mechanistically, Qu improved lysosomal function and suppressed NF-κB-mediated neuroinflammatory response, leading to less production of pro-inflammatory cytokines. Notably, co-administration of a lysosomal inhibitor attenuated the neuroprotective effects of Qu, underscoring the functional importance of lysosomal activation. In conclusion, Qu alleviates CCH-induced cognitive decline and neurodegeneration by restoring lysosomal function and inhibiting NF-κB-driven neuroinflammation. These findings support the therapeutic potential of Qu for VCI and provide a rationale for its further development as a neuroprotective agent.

Keywords

Quercetin / Chronic cerebral hypoperfusion / Lysosomal activation / Neuroinflammation / NF-κB signaling

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Zlokovic BV, Gottesman RF, Bernstein KE . Vascular contributions to cognitive impairment and dementia (VCID): a report from the 2018 national heart, lung, and blood institute and national institute of neurological disorders and stroke workshop. Alzheimers Dement. 2020; 16(12):1714-1733. https://doi.org/10.1002/alz.12157.

[2] Rundek T, Tolea M, Ariko T . Vascular cognitive impairment (VCI). Neurotherapeutics. 2022; 19(1):68-88. https://doi.org/10.1007/s13311-021-01170-y.

[3] Tian ZM, Ji XM, Liu J . Neuroinflammation in vascular cognitive impairment and dementia: current evidence, advances, and prospects. Int J Mol Sci. 2022; 23(11):6224. https://doi.org/10.3390/ijms23116224.

[4] Badji A, Youwakim J, Cooper A . Vascular cognitive impairment - past, present, and future challenges. Ageing Res Rev. 2023; 90:102042. https://doi.org/10.1016/j.arr.2023.102042.

[5] Deepika, Maurya PK . Health benefits of quercetin in age-related diseases. Molecules. 2022; 27(8):2498. https://doi.org/10.3390/molecules27082498.

[6] Zanon Zotin MC, Sveikata L, Viswanathan A . Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. Curr Opin Neurol. 2021; 34(2):246-257. https://doi.org/10.1097/WCO.0000000000000913.

[7] Rizzollo F, More S, Vangheluwe P . The lysosome as a master regulator of iron metabolism. Trends Biochem Sci. 2021; 46(12):960-975. https://doi.org/10.1016/j.tibs.2021.07.003.

[8] Zhang Z, Yue P, Lu T. Role of lysosomes in physiological activities, diseases, and therapy. J Hematol Oncol. 2021; 14(1):79. https://doi.org/10.1186/s13045-021-01087-1.

[9] Root J, Merino P, Nuckols A . Lysosome dysfunction as a cause of neurodegenerative diseases: lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol Dis. 2021; 154:105360. https://doi.org/10.1016/j.nbd.2021.105360.

[10] Pandey MK . Exploring pro-inflammatory immunological mediators: unraveling the mechanisms of neuroinflammation in lysosomal storage diseases. Biomedicines. 2023; 11(4):1067. https://doi.org/10.3390/biomedicines11041067.

[11] Nixon RA, Rubinsztein DC . Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024; 25(11):926-946. https://doi.org/10.1038/s41580-024-00757-5.

[12] Izco M, Carlos E, Alvarez-Erviti L . Impact of endolysosomal dysfunction upon exosomes in neurodegenerative diseases. Neurobiol Dis. 2022; 166:105651. https://doi.org/10.1016/j.nbd.2022.105651.

[13] Filippone A, Esposito E, Mannino D . The contribution of altered neuronal autophagy to neurodegeneration. Pharmacol Ther. 2022; 238:108178. https://doi.org/10.1016/j.pharmthera.2022.108178.

[14] Quick JD, Silva C, Wong JH . Lysosomal acidification dysfunction in microglia: an emerging pathogenic mechanism of neuroinflammation and neurodegeneration. J Neuroinflammation. 2023; 20(1):185. https://doi.org/10.1186/s12974-023-02866-y.

[15] Wei HQ, Chen YX, Qin ZM, et al. Artesunate demonstrates neuroprotective effect through activation of lysosomal function and inhibition of cGAS-STING pathway. Neuropharmacology. 2025; 272:110426, https://doi.org/10.1016/j.neuropharm.2025.110426.

[16] Zhang ML, Lu HF, Xie XS, et al. TMEM175 mediates Lysosomal function and participates in neuronal injury induced by cerebral ischemia-reperfusion. Mol Brain. 2020; 13(1):113. https://doi.org/10.1186/s13041-020-00651-z.

[17] Lipton P. Lysosomal membrane permeabilization as a key player in brain ischemic cell death: a “lysosomocentric” hypothesis for ischemic brain damage. Transl Stroke Res . 2013; 4(6):672-684. https://doi.org/10.1007/s12975-013-0301-2.

[18] Aghababaei F, Hadidi M . Recent advances in potential health benefits of Quercetin. Pharmaceuticals (Basel). 2023; 16(7):1020. https://doi.org/10.3390/ph16071020.

[19] Batiha GE, Beshbishy AM, Ikram M . The pharmacological activity, biochemical properties, and pharmacokinetics of the major natural polyphenolic flavonoid: Quercetin. Foods. 2020; 9(3):374. https://doi.org/10.3390/foods9030374.

[20] Zamanian MY, Soltani A, Khodarahmi Z . Targeting Nrf2 signaling pathway by quercetin in the prevention and treatment of neurological disorders: an overview and update on new developments. Fundam Clin Pharmacol. 2023; 37(6):1050-1064. https://doi.org/10.1111/fcp.12926.

[21] Zhong Y, Li XY, Liang TJ . Effects of NLRP3 inflammasome mediated pyroptosis on cardiovascular diseases and intervention mechanism of Chinese medicine. Chin J Integr Med. 2024; 30(5):468-479. https://doi.org/10.1007/s11655-024-3655-2.

[22] Espírito-Santo DA, Cordeiro GS, Santos LS . Cardioprotective effect of the quercetin on cardiovascular remodeling and atherosclerosis in rodents fed a high-fat diet: a systematic review. Chem Biol Interact. 2023; 384:110700. https://doi.org/10.1016/j.cbi.2023.110700.

[23] Wang ZX, Ma J, Li XY . Quercetin induces p53-independent cancer cell death through lysosome activation by the transcription factor EB and reactive oxygen species-dependent ferroptosis. Br J Pharmacol. 2021; 178(5):1133-1148. https://doi.org/10.1111/bph.15350.

[24] Szalay G, Judák L, Katona G . Fast 3D imaging of spine, dendritic, and neuronal assemblies in behaving animals. Neuron. 2016; 92(4):723-738. https://doi.org/10.1016/j.neuron.2016.10.002.

[25] Ferrari V, Tedesco B, Cozzi M . Lysosome quality control in health and neurodegenerative diseases. Cell Mol Biol Lett. 2024; 29(1):116. https://doi.org/10.1186/s11658-024-00633-2.

[26] Wang Y, Peng L, Lu X . Tangshen Formula protects against podocyte apoptosis via enhancing the TFEB-mediated autophagy-lysosome pathway in diabetic nephropathy. J Ethnopharmacol. 2024; 324:117721. https://doi.org/10.1016/j.jep.2024.117721.

[27] Dajas F, Abin-Carriquiry JA, Arredondo F. Quercetin in brain diseases: potential and limits. Neurochem Int. 2015; 89:140-148. https://doi.org/10.1016/j.neuint.2015.07.002.

[28] Jin Z, Ke J, Guo P . Quercetin improves blood-brain barrier dysfunction in rats with cerebral ischemia reperfusion via Wnt signaling pathway. Am J Transl Res. 2019; 11(8):4683-4695

[29] Yao Y, Han DD, Zhang T. Quercetin improves cognitive deficits in rats with chronic cerebral ischemia and inhibits voltage-dependent sodium channels in hippocampal CA1 pyramidal neurons. Phytother Res. 2010; 24(1):136-140. https://doi.org/10.1002/ptr.2902.

[30] Yang Q, Yang C, Lv H . Autophagy regulation attenuates neuroinflammation and cognitive decline in an Alzheimer’s disease mouse model with chronic cerebral hypoperfusion. Inflammation. 2025; 48(2):541-556. https://doi.org/10.1007/s10753-024-02043-0.

[31] Pang XW, Chu YH, Zhou LQ . Trem2 deficiency attenuates microglial phagocytosis and autophagic-lysosomal activation in white matter hypoperfusion. J Neurochem. 2023; 167(4):489-504. https://doi.org/10.1111/jnc.15987.

[32] Li Y, Chen M, Xu Y . Iron-mediated lysosomal membrane permeabilization in ethanol-induced hepatic oxidative damage and apoptosis: protective effects of quercetin. Oxid Med Cell Longev. 2016; 2016:4147610. https://doi.org/10.1155/2016/4147610.

[33] Zhao Y, Li ZF, Zhang D . Quercetin alleviates Cadmium-induced autophagy inhibition via TFEB-dependent lysosomal restoration in primary proximal tubular cells. Ecotoxicol Environ Saf. 2021; 208:111743. https://doi.org/10.1016/j.ecoenv.2020.111743.

[34] Biswas K. Microglia mediated neuroinflammation in neurodegenerative diseases: a review on the cell signaling pathways involved in microglial activation. J Neuroimmunol. 2023; 383:578180. https://doi.org/10.1016/j.jneuroim.2023.578180.

[35] Li L, Jiang W, Yu B . Quercetin improves cerebral ischemia/reperfusion injury by promoting microglia/macrophages M2 polarization via regulating PI3K/Akt/NF-κB signaling pathway. Biomed Pharmacother. 2023; 168:115653. https://doi.org/10.1016/j.biopha.2023.115653.

[36] Kim SR, Park Y, Li M . Anti-inflammatory effect of Ailanthus altissima (Mill.) Swingle leaves in lipopolysaccharide-stimulated astrocytes. J Ethnopharmacol. 2022; 286:114258. https://doi.org/10.1016/j.jep.2021.114258.

[37] Xiong J, Zhu MX . Regulation of lysosomal ion homeostasis by channels and transporters. Sci China Life Sci. 2016; 59(8):777-791. https://doi.org/10.1007/s11427-016-5090-x.

[38] Kendall RL, Holian A . The role of lysosomal ion channels in lysosome dysfunction. Inha Toxicol. 2021; 33(2):41-54. https://doi.org/10.1080/08958378.2021.1876188.

[39] Hornung V, Bauernfeind F, Halle A . Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9(8):847-856. https://doi.org/10.1038/ni.1631.

[40] Ren SC, Suo QF, Du WT . Quercetin permeability across blood-brain barrier and its effect on the viability of U251 cells. J Sichuan University (Medical science edition). 2010; 41(5):751-754

[41] Duc Nguyen H. Neurotherapeutic effects of Quercetin and its metabolite compounds on cognitive impairment and Parkinson’s disease: an in silico study. Eur J Drug Metab Pharmacokinet. 2023; 48(2):151-169. https://doi.org/10.1007/s13318-023-00816-w.

[42] Li Y, Man M, Tian Y . Quercetin protects against neuronal toxicity by activating the PI3K/Akt/GSK-3β pathway in vivo models of MPTP-induced Parkinson’s disease. Inflammopharmacology. 2025; 33(7):4063-4076. https://doi.org/10.1007/s10787-025-01712-2.

[43] Pavlović N, Milošević Sopta N, Mitrović D . Principal component analysis (PCA) of molecular descriptors for improving permeation through the blood-brain barrier of Quercetin analogues. Int J Mol Sci. 2023; 25(1):192. https://doi.org/10.3390/ijms25010192.

[44] Calabrese P, Sitek EJ, Korczyn AD. The assessment of cognitive and behavioural disturbances in vascular cognitive impairment (VCI) - recommendations of an expert working group. Neurol Neurochir Pol. 2021; 55(4):333-345. https://doi.org/10.5603/pjnns.a2021.0035.

[45] Chen J, Mao K, Yu H . p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson’s disease. J Neuroinflammation. 2021; 18(1):295. https://doi.org/10.1186/s12974-021-02349-y.

[46] Lee J, Kim H, Kim J . A novel treatment strategy by natural products in NLRP3 Inflammasome-mediated neuroinflammation in Alzheimer’s and Parkinson’s disease. Int J Mol Sci. 2021; 22(3):1324. https://doi.org/10.3390/ijms22031324.

[47] Wang ZL, Yuan L, Li W . Ferroptosis in Parkinson's disease: glia-neuron crosstalk. Trends Mol Med. 2022; 28(4):258-269. https://doi.org/10.1016/j.molmed.2022.02.003.